Open Menu Close Menu Open Search Close Search Open Directory Close Directory

Effects of chemotherapy on blood clotting in dogs with hemangiosarcoma

Evaluation of Coagulation Parameters in Canine Splenic Hemangiosarcoma Patients Undergoing a Doxorubicin-based Chemotherapy Protocol

Status: Recruiting

Species: Dog

Veterinary Speciality: Emergency Critical Care, Internal Medicine, Oncology

Description

Evaluation of Coagulation Parameters in Canine Splenic Hemangiosarcoma Patients Undergoing a Doxorubicin-based Chemotherapy Protocol

Inclusion Criteria

Dogs with histopathologically diagnosed Stage II splenic hemangiosarcoma (HSA) following splenectomy with no evidence of disease at the time of enrollment based on thoracic radiographs and abdominal ultrasound, and intention to treat with 5 cycles of a doxorubicin-based chemotherapy protocol. 

Exclusion Criteria

Dogs that have received therapies known to affect coagulation, including Vitamin K, blood products, non-steroidal anti-inflammatories, clopidogrel, heparin, rivaroxaban, epixaban, Yunnan Baiyao, or hydroxylethyl starch within 7 days of enrollment. Greyhound dogs and patients with confirmed diseases that affect coagulation, including immune-mediated disease, protein-losing nephropathy, protein-losing enteropathy, and hyperadrenocorticism will also be excluded. 

Client Benefits

All coagulation testing (t-PA TEG, PT/PTT, fibrinogen, and D-dimers) will be covered by the study. Owners will be expected to pay for the complete blood count, as it is part of the standard chemotherapy protocol.

Sample or Data Requirements

Measurement of coagulation profiles will coincide with a routine re-staging schedule during a doxorubicin chemotherapy protocol; prior to initiation of chemotherapy, at the time of the third and fifth doxorubicin treatments, and monthly thereafter until recognition of metastatic disease. A complete blood count and t-PA TEG will be run at each of the aforementioned timepoints; samples for PT/PTT, fibrinogen, and D-dimers will be frozen for batch analysis. If metastatic disease is detected at any intermediate timepoint, a final coagulation sample will be collected. 

Contact Info

For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: clinicaltrials@tufts.edu

Print Friendly, PDF & Email